It seems likely that palbociclib is able to arrest cell cycle progression through both direct and indirect mechanisms, meaning the sensitivity of a cancer cell to palbociclib may be dependent upon both its reliance on CDK4/6 activity for cell cycle entry and the relative expression levels of p21/p27. This evidence concerns the gene CDKN1A and cancer.